tirzepatide

News

Real-world trial of Lilly's tirzepatide starts in UK

A real-world study exploring the long-term effects of Eli Lilly's weight-loss therapy tirzepatide in primary care settings has started in the UK.

News

Small study finds GLP-1 drug can curb excess alcohol use

Novo Nordisk's GLP-1 receptor agonist semaglutide has been shown to help people struggling with alcohol use disorder.

News

female scientist conducting experiment in a laboratory

Tirzepatide gets a big win in obesity-related heart failure

Eli Lilly's tirzepatide has been shown to significantly cut cardiovascular risks in patients with obesity and a form of heart failure with few treatment options, in another big win for the

News

Lilly pledges £279m to UK for biotech hub and obesity plan

Eli Lilly has said it is prepared to invest £279 million ($364 million) in the UK and work with the government to tackle serious public health challenges, including obesity.

News

Mounjaro and Zepbound shortages over, declares FDA

The US Food and Drug Administration (FDA) has declared an end to the shortage of tirzepatide, the active ingredient in

News

Lilly says tirzepatide staves off diabetes in phase 3 trial

Eli Lilly's latest clinical readout for dual GIP/GLP-1 agonist tirzepatide is a big one, with data suggesting the drug can reduce the risk of developing type 2 diabetes in overweight and ob

Real-world trial of Lilly's tirzepatide starts in UK

Small study finds GLP-1 drug can curb excess alcohol use

Tirzepatide gets a big win in obesity-related heart failure

Lilly pledges £279m to UK for biotech hub and obesity plan

Mounjaro and Zepbound shortages over, declares FDA

Lilly says tirzepatide staves off diabetes in phase 3 trial

NHS staff 'feel unprepared for digital transformation'

How to meet your physicians where they are online

tirzepatide

Editor's Picks